覆盖 1,000+ 靶点|涉及 20+ 信号通路|独家活性分子|众多热点研究领域
| 热门研究靶点 | JAK/STAT signaling: Stattic, Tofacitinib (托法替尼), Ruxolitinib (INCB18424) MAPK/ERK: U0126, SB202190 KRAS: Sotorasib (索拉非尼), Adagrasib (MRTX849), MRTX1133 CSF1R: PLX5622, Pexidartinib, etc. | 
| 细胞程序性死亡相关 | 细胞凋亡和自噬: Z-VAD-FMK, MG-132, 3-MA 铁死亡: Erastin, Ferrostatin-1, RSL3 铜死亡: Elesclomol, Disulfiram | 
| PROTAC 类 | dBET6, ARV-771, LC-2, SD-36 | 
| ADC 毒素 | Doxorubicin, Exatecan (依喜替康), Eribulin (艾日布林) | 
涵盖 100+ 热门靶点|低内毒|精准识别|ADC 偶联|独家活性验证
| 单克隆抗体 | 双特异性抗体 | 融合蛋白 | 同型对照抗体 | 
| Cetuximab (EGFR), Dupilumab (IL-4Rα), Nivolumab (PD-1) | Tebotelimab (PD-1/LAG-3),Epcoritamab (CD3/CD20) | Raleukin (IL-1R), Abatacept (CTLA4) | Mouse lgG2a (D265A) κ, Isotype Control, Human IgG1 κ, Isotype Control, etc. | 
种类多样|固相合成|适应症广泛|靶点丰富
| 核酸适配体 | 反义寡核苷酸 (ASO) | CpG 寡核苷酸 | 脂质纳米颗粒 (LNPs) | 
| AS 1411, Avacincaptadpegol sodium | Nusinersen, Tofersen, Mipomersen | ODN 1826, Agatolimod, ODN 1668 | ALC-0315, SM-102 | 
 
                 
                                 
                        
                     
  
                         
                         
                         
                     
                     
                         
                         
                         
                         
                         
                         
                         
                         
                             
                             
                             
                             
                     
                         
                         
                             
                             
                             
                             
                             
                             
                             
                             
                         
                         
                         
                         
                         
             
                             
                             
                             
        
 
    